Search Result

Results for "

relapsed and refractory multiple myeloma

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibody-Drug Conjugates (ADCs) (1) Apoptosis (4) Autophagy (4) CD3 (1) CD38 (1) HDAC (4) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) HIV (4) Isotope-Labeled Compounds (1) Ras (1) TNF Receptor (1)
By Research Areas:	Cancer (10) Infection (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9989

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .

HY-119264A

PRLX-93936 dihydrochloride	HIF/HIF Prolyl-Hydroxylase Ras	Cancer
PRLX-93936 dihydrochloride (Compound 16) is a HIF-1α inhibitor with anticancer activity. PRLX-93936 can inhibit the activated Ras pathway and can be used in the study of relapsed or refractory multiple myeloma .

HY-144858

EZM0414 4 Publications Verification	Histone Methyltransferase	Cancer
EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 (IC₅₀=18 nM in SETD2 biochemical assay; IC₅₀=34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma .

HY-P99730

Mezagitamab TAK-079	CD38	Cancer
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .

HY-P99454

Azintuxizumab vedotin ABBV-838	Antibody-Drug Conjugates (ADCs)	Cancer
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .

HY-10224

Panobinostat Maximum Cited Publications 58 Publications Verification LBH589; NVP-LBH589	HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities . Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells . Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma .

HY-10224A

Panobinostat lactate LBH589 lactate; NVP-LBH589 lactate	HDAC HIV Autophagy Apoptosis	Infection Cancer
Panobinostat lactate is a potent and orally active non-selective HDAC inhibitor. Panobinostat lactate has antineoplastic activities. Panobinostat lactate effectively disrupts HIV latency. Panobinostat lactate induces cell apoptosis and autophagy. Panobinostat lactate can be used for the study of refractory or relapsed multiple myeloma .

HY-10224S

Panobinostat-d4 LBH589-d₄; NVP-LBH589-d₄	HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride LBH589-d₄ hydrochloride; NVP-LBH589-d₄ hydrochloride	Isotope-Labeled Compounds HDAC Autophagy HIV Apoptosis	Cancer
Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Cat. No.	Product Name	Target	Research Area

HY-P9989

Linvoseltamab REGN5458	CD3 TNF Receptor	Cancer
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .

HY-P9965

Elotuzumab HuLuc 63; PDL 063; BMS 901608	Inhibitory Antibodies	Cancer
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents .

HY-P99730

Mezagitamab TAK-079	CD38	Cancer
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .

HY-P99454

Azintuxizumab vedotin ABBV-838	Antibody-Drug Conjugates (ADCs)	Cancer
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P9989

Linvoseltamab REGN5458	Classification of Application Fields Disease Research Fields Cancer	CD3 TNF Receptor
Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .

HY-P9965

Elotuzumab HuLuc 63; PDL 063; BMS 901608	Classification of Application Fields Disease Research Fields Cancer	Others
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents .

HY-P99730

Mezagitamab TAK-079	Classification of Application Fields Disease Research Fields Cancer	CD38
Mezagitamab (TAK-079) is a IgG1λ anti-CD38 monoclonal antibody. Mezagitamab depletes tumor cells expressing CD38 through antibody and complement dependent cytotoxicity. Mezagitamab has potential application in relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) .

Cat. No.	Product Name	Chemical Structure

HY-10224S

Panobinostat-d4
Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Panobinostat-d4

Panobinostat-d₄ is the deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

HY-10224S1

Panobinostat-d4 hydrochloride
Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Panobinostat-d4 hydrochloride

Panobinostat-d₄ (hydrochloride) is deuterium labeled Panobinostat. Panobinostat (LBH589; NVP-LBH589) is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

relapsed and refractory multiple myeloma

Inhibitors & Agonists

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products